Biocoral, Inc. Announces Approval for Its Patent in Canada.Business Editors NEW YORK--(BUSINESS WIRE)--Feb. 13, 2002 Biocoral, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). :BICR) announced that following its international application (PCT (Private Communications Technology) A protocol from Microsoft that provides secure transactions over the Web. See security protocol. ) for its Autologous autologous /au·tol·o·gous/ (aw-tol´ah-gus) related to self; belonging to the same organism. au·tol·o·gous adj. 1. Biological Surgical Glue, it recently received the approval for its Patent in Canada from the Canadian Intellectual Property Office The Canadian Intellectual Property Office (CIPO) is the patent, trademark, and copyright administration body of Canada. See also
The Canadian Intellectual Property Office, after more than five years examination of the company's application, granted the patent innovation which is valid until March 31, 2015, twenty years from the date of its application on March 31, 1995. The Company's medical device permits the preparation of its Autologous Biological Surgical Glue that Company management believes to be the world's first fully autologous fibrin glue, which is prepared using the patient's own blood in a close system eliminating immunological problem and the risk of blood borne disease transmission such as HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and Hepatitis. In contrast, all fibrin glues currently on the market (whether autologous or homologous) require foreign proteins such as thrombin or antifibrinolytic agents. Nasser Nassiri, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Biocoral, Inc. said: "The Company completed phase III of human clinical trials in specific indication in Europe and obtained the authorization for the preparation, use and distribution of its new autologous fibrin glue in France from the appropriate French authorities (AFFSAPS) and now after obtaining its patent in Canada, the company is actively seeking an accredited accredited recognition by an appropriate authority that the performance of a particular institution has satisfied a prestated set of criteria. accredited herds cattle herds which have achieved a low level of reactors to, e.g. Canadian or North American distributor for preparing and distributing its Autologous Biological Surgical Glue." Company management believes that the world market segments for the autologous fibrin glue is in excess of $600 million. Biocoral, Inc., a Delaware corporation, (the "Company") is an international biotechnology company specializing in the research, development and commercialization of patented high biotechnologies and biomaterials in the health care area. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion